PCSK9 and Thrombo-inflammatory Pathways

Proprotein convertase subtilisin/kexin type 9 (PCSK9) was characterized as a hepatic regulator of low-density lipoprotein receptor (LDLR) degradation. Monoclonal antibodies directed at PCSK9 lower low-density lipoprotein cholesterol (LDL-C) and reduce major adverse cardiovascular events; small interfering RNA directed at PCSK9 lowers LDL-C, and cardiovascular outcome testing is ongoing. A parallel body of work has since linked PCSK9 to thrombo-inflammatory processes. Experimental studies indicate that extracellular PCSK9 activates platelets through CD36, induces monocyte tissue factor expression via Toll-like receptor 4 and nuclear factor-κB, promotes release of procoagulant extracellular vesicles, and impairs endothelial homeostasis; PCSK9 may also raise factor VIII by accelerating turnover of LDLR family members. Clinical biomarker studies report lower platelet-activation markers, and fibrinogen and plasminogen activator inhibitor-1 during treatment. However, randomized placebo-controlled studies using direct platelet-function assays, as well as their pooled analysis, have not demonstrated a consistent reduction in platelet reactivity with PCSK9 monoclonal antibodies. This review synthesizes and evaluates the evidence by cellular compartment, separating circulating, locally released and intracellular PCSK9, and by evidentiary level, separating preclinical mechanism, observational association, circulating biomarker, randomized pharmacodynamic endpoint, clinical outcome, and human genetics. It also examines why experimental findings may not translate into measurable platelet inhibition in treated patients, and how concomitant antithrombotic and statin therapy conditions any such measurement. Preclinical plausibility is substantial. A clinically measurable, LDL-independent antiplatelet effect of PCSK9 inhibition has not been established, and the randomized evidence is more precise against a large platelet effect than against a modest one.